John W. Ripple
Chief Executive Officer at Exonics Therapeutics, Inc.
Profile
John W.
Ripple is the founder of Permeon Biologics, Inc. He currently holds the position of Chief Executive Officer & Director at Exonics Therapeutics, Inc., Director at Praesidia Biotherapeutics, Inc., and Treasurer & Executive Director at Children's Melanoma Prevention Foundation.
Previously, he served as Chief Executive Officer & Director at Ensemble Therapeutics Corp., Chief Executive Officer at Bioverativ Therapeutics, Inc., and Director-Corporate Development at Genetics Institute LLC.
He also held the position of Vice President-Global Business Development at Wyeth Pharmaceuticals LLC and worked as an Aerospace Engineer at National Aeronautics & Space Administration.
Mr. Ripple received his undergraduate degree from Bucknell University and his MBA from Harvard Business School.
John W. Ripple active positions
| Companies | Position | Start |
|---|---|---|
Exonics Therapeutics, Inc.
 Exonics Therapeutics, Inc. BiotechnologyHealth Technology Exonics Therapeutics, Inc. develops therapies for neuromuscular diseases. It also develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of duchenne muscular dystrophy mutations. The company was founded by Eric N. Olson in February 2017 and is headquartered in Cambridge, MA. | Chief Executive Officer | - |
Children's Melanoma Prevention Foundation
 Children's Melanoma Prevention Foundation Miscellaneous Commercial ServicesCommercial Services Part of Melanoma Research Foundation, Children's Melanoma Prevention Foundation is a non-profit educational foundation that provides video lessons and programs to educate and prevent skin cancer. The company is based in Hingham, MA. The company was founded in 2003. Children's Melanoma Prevention Foundation was acquired by Melanoma Research Foundation on November 02, 2021. | Director/Board Member | - |
Praesidia Biotherapeutics, Inc.
 Praesidia Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Praesidia Biotherapeutics, Inc. is a company that specializes in developing drugs using their proprietary Tunable Linker Technology called LESS (Linker Enzyme Substrate System). The company is based in Arlington, MA. This technology helps to maximize the therapeutic potential of drugs. The company was founded by Sohang Chatterjee, Pradip K. Majumder, and Santosh Kesari, with Sohang Chatterjee serving as the CEO since incorporation. | Director/Board Member | - |
Former positions of John W. Ripple
| Companies | Position | End |
|---|---|---|
Virdante Pharmaceuticals, Inc.
 Virdante Pharmaceuticals, Inc. Medical DistributorsDistribution Services Virdante Pharmaceuticals, Inc. develops and commercializes drugs for auto-immune and inflammatory disorders. The company's products incorporate a proprietary 'sialic switch' technology to improve the anti-inflammatory properties of antibodies. It was founded in 2008 and is headquartered in Cambridge, MA. | Chief Executive Officer | 30/01/2012 |
Ensemble Therapeutics Corp.
 Ensemble Therapeutics Corp. Chemicals: Major DiversifiedProcess Industries Ensemble Therapeutics Corp. develops novel classes of therapeutics and bioassays for research and diagnostics. The firm focuses on the discovery and development of breakthrough small molecule therapies for patients with cancer and other serious diseases. The company was founded by Douglas G. Cole, Noubar B. Afeyan and David R. Liu in 2004 and is headquartered in Cambridge, MA. | Chief Executive Officer | - |
Permeon Biologics, Inc.
 Permeon Biologics, Inc. BiotechnologyHealth Technology Permeon Biologics, Inc. develops intracellular biotherapeutics platform to enhance drug delivery. Its intraphilin technology platform leverages research on remodeling the surfaces of proteins to permit cell penetration without losing their structure or activity; and enables functional proteins to replace or restore defective pathways inside cells that cause disease. The company was founded by Douglas G. Cole, David R. Liu, John W. Ripple, and Noubar B. Afeyan in 2008 and is headquartered in Cambridge, MA. | Chief Executive Officer | - |
| National Aeronautics & Space Administration | Corporate Officer/Principal | - |
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Training of John W. Ripple
| Bucknell University | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
Ensemble Therapeutics Corp.
Ensemble Therapeutics Corp. Chemicals: Major DiversifiedProcess Industries Ensemble Therapeutics Corp. develops novel classes of therapeutics and bioassays for research and diagnostics. The firm focuses on the discovery and development of breakthrough small molecule therapies for patients with cancer and other serious diseases. The company was founded by Douglas G. Cole, Noubar B. Afeyan and David R. Liu in 2004 and is headquartered in Cambridge, MA. | Process Industries |
Bioverativ Therapeutics, Inc.
 Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. | Health Technology |
Wyeth Pharmaceuticals LLC
 Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Health Technology |
Virdante Pharmaceuticals, Inc.
Virdante Pharmaceuticals, Inc. Medical DistributorsDistribution Services Virdante Pharmaceuticals, Inc. develops and commercializes drugs for auto-immune and inflammatory disorders. The company's products incorporate a proprietary 'sialic switch' technology to improve the anti-inflammatory properties of antibodies. It was founded in 2008 and is headquartered in Cambridge, MA. | Distribution Services |
| National Aeronautics & Space Administration | Government |
Permeon Biologics, Inc.
Permeon Biologics, Inc. BiotechnologyHealth Technology Permeon Biologics, Inc. develops intracellular biotherapeutics platform to enhance drug delivery. Its intraphilin technology platform leverages research on remodeling the surfaces of proteins to permit cell penetration without losing their structure or activity; and enables functional proteins to replace or restore defective pathways inside cells that cause disease. The company was founded by Douglas G. Cole, David R. Liu, John W. Ripple, and Noubar B. Afeyan in 2008 and is headquartered in Cambridge, MA. | Health Technology |
Exonics Therapeutics, Inc.
Exonics Therapeutics, Inc. BiotechnologyHealth Technology Exonics Therapeutics, Inc. develops therapies for neuromuscular diseases. It also develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of duchenne muscular dystrophy mutations. The company was founded by Eric N. Olson in February 2017 and is headquartered in Cambridge, MA. | Health Technology |
Praesidia Biotherapeutics, Inc.
Praesidia Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Praesidia Biotherapeutics, Inc. is a company that specializes in developing drugs using their proprietary Tunable Linker Technology called LESS (Linker Enzyme Substrate System). The company is based in Arlington, MA. This technology helps to maximize the therapeutic potential of drugs. The company was founded by Sohang Chatterjee, Pradip K. Majumder, and Santosh Kesari, with Sohang Chatterjee serving as the CEO since incorporation. | Health Services |
Children's Melanoma Prevention Foundation
Children's Melanoma Prevention Foundation Miscellaneous Commercial ServicesCommercial Services Part of Melanoma Research Foundation, Children's Melanoma Prevention Foundation is a non-profit educational foundation that provides video lessons and programs to educate and prevent skin cancer. The company is based in Hingham, MA. The company was founded in 2003. Children's Melanoma Prevention Foundation was acquired by Melanoma Research Foundation on November 02, 2021. | Commercial Services |
- Stock Market
- Insiders
- John W. Ripple